Coherus Distances Itself From Biosimilar Interchangeability

US Humira Biosimilars May Feature Designation In 2023

07 May 2021

Coherus BioSciences has had its say on the prospect of interchangeability for Humira biosimilars, shortly after Boehringer Ingelheim announced positive data from a ‘first-of-its-kind’ switching study.

Railway tracks with switches and interchanges at a main line in Germany with geometrical structures black and white — A lack of interchangeability has not hindered biosimilar uptake in Europe, Coherus argues • Source: Shutterstock

Coherus BioSciences has confirmed it is not seeking to conduct any biosimilar interchangeability study for its proposed biosimilar Humira (adalimumab) product ahead of US market formation in 2023, stressing that it will not be required in order for the company to be competitive.

Boehringer Ingelheim and Pfizer are known to be chasing actively the controversial designations for interchangeability for their biosimilar adalimumab products,...